|Guidelines on nicotine dose selection for in vivo research|
SG Matta, DJ Balfour, NL Benowitz, RT Boyd, JJ Buccafusco, ...
Psychopharmacology 190 (3), 269-319, 2007
W Kalow, DM Grant
Heredity and the response to drugs. London: Saunders Company 12, 1962
|Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct …|
T Aoyama, S Yamano, DJ Waxman, DP Lapenson, UA Meyer, V Fischer, ...
Journal of Biological Chemistry 264 (18), 10388-10395, 1989
|Nicotine metabolism defect reduces smoking|
ML Pianezza, EM Sellers, RF Tyndale
Nature 393 (6687), 750-750, 1998
|A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes|
ES Messina, RF Tyndale, EM Sellers
Journal of Pharmacology and Experimental Therapeutics 282 (3), 1608-1614, 1997
|Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity|
D Dempsey, P Tutka, P Jacob III, F Allen, K Schoedel, RF Tyndale, ...
Clinical Pharmacology & Therapeutics 76 (1), 64-72, 2004
|Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians|
KA Schoedel, EB Hoffmann, Y Rao, EM Sellers, RF Tyndale
Pharmacogenetics and Genomics 14 (9), 615-626, 2004
|Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence|
V Malaiyandi, EM Sellers, RF Tyndale
Clinical Pharmacology & Therapeutics 77 (3), 145-158, 2005
|Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking|
Y Rao, E Hoffmann, M Zia, L Bodin, M Zeman, EM Sellers, RF Tyndale
Molecular Pharmacology 58 (4), 747-755, 2000
|Nicotine-dependence symptoms are associated with smoking frequency in adolescents|
J O'Loughlin, J DiFranza, RF Tyndale, G Meshefedjian, E McMillan-Davey, ...
American journal of preventive medicine 25 (3), 219-225, 2003
|Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation|
C Lerman, R Tyndale, F Patterson, EP Wileyto, PG Shields, A Pinto, ...
Clinical Pharmacology & Therapeutics 79 (6), 600-608, 2006
|Genetics of alcohol and tobacco use in humans|
Annals of medicine 35 (2), 94-121, 2003
|The pharmacogenetics research network: from SNP discovery to clinical drug response|
KM Giacomini, CM Brett, RB Altman, NL Benowitz, ME Dolan, ...
Clinical Pharmacology & Therapeutics 81 (3), 328-345, 2007
|Inhibition of cytochromes P450 by antifungal imidazole derivatives|
W Zhang, Y Ramamoorthy, T Kilicarslan, H Nolte, RF Tyndale, EM Sellers
Drug Metabolism and Disposition 30 (3), 314-318, 2002
|The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H] GBR-12935 binding proteins|
HB Niznik, RF Tyndale, FR Sallee, FJ Gonzalez, JP Hardwick, T Inaba, ...
Archives of Biochemistry and Biophysics 276 (2), 424-432, 1990
|Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain|
S Miksys, C Lerman, PG Shields, DC Mash, RF Tyndale
Neuropharmacology 45 (1), 122-132, 2003
|CYP2A6 genotype and the metabolism and disposition kinetics of nicotine|
NL Benowitz, GE Swan, P Jacob III, CN Lessov‐Schlaggar, RF Tyndale
Clinical Pharmacology & Therapeutics 80 (5), 457-467, 2006
|Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking|
EM Sellers, HL Kaplan, RF Tyndale
Clinical Pharmacology & Therapeutics 68 (1), 35-43, 2000
|Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy|
V Malaiyandi, C Lerman, NL Benowitz, C Jepson, F Patterson, ...
Molecular psychiatry 11 (4), 400-409, 2006
|Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study|
RA Schnoll, F Patterson, EP Wileyto, RF Tyndale, N Benowitz, C Lerman
Pharmacology Biochemistry and Behavior 92 (1), 6-11, 2009